Glycogen Synthase Kinase 3: Ion Channels, Plasticity, and Diseases.

Mate Marosi, Parsa Arman, Giuseppe Aceto, Marcello D'Ascenzo, Fernanda Laezza

Journal: International journal of molecular sciences 2022;23(8):4413

PMID: 35457230

Abstract

Glycogen synthase kinase 3β (GSK3) is a multifaceted serine/threonine (S/T) kinase expressed in all eukaryotic cells. GSK3β is highly enriched in neurons in the central nervous system where it acts as a central hub for intracellular signaling downstream of receptors critical for neuronal function. Unlike other kinases, GSK3β is constitutively active, and its modulation mainly involves inhibition via upstream regulatory pathways rather than increased activation. Through an intricate converging signaling system, a fine-tuned balance of active and inactive GSK3β acts as a central point for the phosphorylation of numerous primed and unprimed substrates. Although the full range of molecular targets is still unknown, recent results show that voltage-gated ion channels are among the downstream targets of GSK3β. Here, we discuss the direct and indirect mechanisms by which GSK3β phosphorylates voltage-gated Na channels (Na1.2 and Na1.6) and voltage-gated K channels (K4 and K7) and their physiological effects on intrinsic excitability, neuronal plasticity, and behavior. We also present evidence for how unbalanced GSK3β activity can lead to maladaptive plasticity that ultimately renders neuronal circuitry more vulnerable, increasing the risk for developing neuropsychiatric disorders. In conclusion, GSK3β-dependent modulation of voltage-gated ion channels may serve as an important pharmacological target for neurotherapeutic development.

Address: Department of Pharmacology & Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA.; Department of Neuroscience, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.; Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, 00168 Roma, Italy.; Center for Addiction Research, Center for Biomedical Engineering, Mitchell Center for Neurodegenerative Diseases, Department of Pharmacology & Toxicology, 301 University Boulevard, Galveston, TX 77555, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.